ShoreHaven Wealth Partners’s Moderna MRNA Stock Holding History

ShoreHaven Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-30	Closed	-$4K	–	182
2021 Q1	$4K	Buy	+30	New	+$4.35K	﹤0.01%	228

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

ShoreHaven Wealth Partners's MRNA Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Moderna (MRNA) in Q2 2021, closing a stake of 30 shares — an estimated $4K sold.

ShoreHaven Wealth Partners first reported a position in MRNA in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 905 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

ShoreHaven Wealth Partners reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
ShoreHaven Wealth Partners sold 30 Moderna shares in Q2 2021, an estimated $4K.
ShoreHaven Wealth Partners first reported a position in Moderna in Q1 2021 and held it in 1 quarter.
ShoreHaven Wealth Partners's Moderna position peaked at $4K in Q1 2021.
905 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.